Lisa Salberg to testify on generic drug quality before Senate panel

By AI, Created 7:56 PM UTC, June 02, 2026, /AGP/ – Lisa Salberg, founder and CEO of the Hypertrophic Cardiomyopathy Association, is set to testify June 3 before the Senate Committee on Aging on the human impact of generic drug quality and production standards. The hearing could push Congress toward tighter oversight, clearer labeling and possible updates to federal drug law.

Why it matters: - Generic drugs make up a major share of prescriptions, so quality gaps can affect millions of patients. - Salberg’s testimony is aimed at stronger oversight, clearer country-of-origin and manufacturing disclosures, and better testing standards for drug absorption. - Any policy shift could shape how regulators and manufacturers define and review generic drug quality.

What happened: - Lisa Salberg, CEO and founder of the New Jersey-based Hypertrophic Cardiomyopathy Association, will testify before the U.S. Senate Committee on Aging on Wednesday, June 3, 2026. - The hearing is titled “Poisoned Pills: The Human Cost of Dangerous Foreign Drugs.” - The hearing is scheduled for 3:30 p.m. EDT in the Hart Senate Office Building, Room 216, and will stream live on the Senate Committee on Aging website.

The details: - Salberg plans to focus on the human impact of current generic drug policy and production infrastructure. - Her prepared remarks say consumers do not always know whether a generic drug matches the brand-name version. - Salberg said the current system does not clearly tell consumers where active pharmaceutical ingredients come from, where a generic is manufactured and bottled, or how distribution is documented. - Salberg said government oversight should ensure that people of all income and education levels can understand that information. - She said “70% of generic drugs are safe,” while “30% may not absorb properly,” and said some may contain toxins or carcinogens. - Salberg will advocate for updates to the Hatch-Waxman Act, enacted in 1984. - She wants new testing requirements for dissolution rates to confirm that drugs are being absorbed properly. - Salberg also plans to offer bipartisan legislative and federal policy recommendations to define generic drug quality and standardize quality review processes. - Media inquiries and interview requests can be directed to Claudine D’Angelo-Dotzman at claudine@4hcm.org or (973) 983-7429 X-415. - An advance copy of the testimony is available by request.

Between the lines: - The testimony ties patient safety to supply-chain transparency, not just price. - Salberg’s push for dissolution testing suggests concern that bioequivalence on paper may not always translate into reliable performance in real-world use. - The hearing name signals a broader Senate focus on foreign manufacturing and drug-quality risk.

What’s next: - Salberg will deliver her testimony on June 3 before the Senate Committee on Aging. - The hearing could inform future bipartisan legislation or federal rule changes on generic drug quality. - The HCMA says its policy work will continue alongside patient support, research and health-care advocacy.

The bottom line: - The hearing puts generic drug quality, manufacturing transparency and patient safety directly in front of lawmakers.